Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. ("Solterra") and the other lenders, for its Melz solar PV project in Germany.

The Addendum follows a share purchase agreement under which Solterra and its assets are being sold to Sunflower Sustainable Investments Ltd. As a result, Solterra is making early partial repayments of the loan. The Addendum, executed together with the other lenders, includes an early partial loan repayment and reduction of profit rights. The transaction reflects a total project valuation of $14.5 million, representing a significant premium to the Company’s initial investment.

In connection with the transaction, the group of lenders, in which Nexentis holds the majority share, provided a total commitment of approximately $2.95 million (of which Nexentis accounts for approximately $2.18 million) to bring the 115 MWp Melz project to RTB stage. Under the Addendum, Nexentis will receive an early repayment of approximately $147,000 (including accrued interest) on its portion of the loan, plus $98,000 for the sale of 10% of its profit rights (representing 2.5% of the project’s profits)) and an additional $22,000 as an option fee for the right to purchase the remaining profit rights at RTB based on an independent Big 4 valuation. The transaction reflects a total project valuation of $14.5 million ($120,000 per MW), representing a significant premium to the Company’s initial investment.